|Reported adverse drug reactions|
Chen C, et al.|
Antiviral-associated adverse effects among favipiravir group were (n, %):|
Abnormal LFT, 10 (8.62); Raised serum uric acid, 16 (13.79); Psychiatric symptoms reactions, 5 (4.31); Digestive tract reactions, 16 (13.79)
|Among arbidol group (n, %): Abnormal LFT, 12 (10.00); Raised serum uric acid, 3 (2.50); Psychiatric symptoms reactions, 1 (0.83); Digestive tract reactions, 14 (11.67)|
|Lou Y, et al.||Respiratory failure occurred in 14 patients. Other adverse events were generally mild or moderate among the three Groups. The most frequent adverse events 2 occurring in the study population were similar among all groups, including elevation of 3 triglyceride (20 events), liver function abnormality (18 events), rash (7 events), and diarrhea (4 events). No abnormal 5 serum creatinine was found in all patients.|
Ivashchenko AA, et al.|
Adverse drug reactions were reported in 7/40 (17.5%) patients, including diarrhea, nausea, vomiting, chest pain and an increase in liver transaminase levels.|
The adverse drug reactions were mild to moderate and caused early discontinuation of the study drug in 2/40 (5.0%)
|Cai Q, et al.||
Total numbers of adverse reactions were 4 in favipiravir|
5.71% reported diarrhea, respectively.
None of reported for vomiting, nausa, and rash.
Total numbers of adverse reactions were 24 in LPV/RTV groups.|
11.11% reported diarrhea, respectively.
11.1, 13.33, 8.89% of LPV/RTV group reported vomiting, nausa, and rash, respectively.
Doi Y, et al.|
Among 82 patients, total 144 adverse events.|
The most common was hyperuricemia (84.1%).
Of 32 patients who had serum uric acid level determined, 24 had the level normalized to below 7 mg/dL, with the highest being 8.8 mg/dL.
Serum triglyceride elevation (11.0%)
Serum alanine aminotransferase elevation (8.5%).